Who is affected and how:

• People with epilepsy and their families/caregivers: Likely to benefit from better-coordinated prevention, diagnosis, treatment, education, and support services; potential for improved clinical guidance and research that could reduce seizures and related harms. Caregivers may see improved resources and guidance.
• Health care providers and the health care workforce: May receive updated clinical guidance, training resources, and public health tools to improve diagnosis and management of epilepsy.
• Researchers and research institutions: Expect greater coordination, access to shared federal data, and clearer research priorities that could accelerate trials and discovery. Increased data sharing may improve study quality and surveillance.
• Federal agencies and HHS: Must allocate staff time and existing resources to plan development, data sharing, reporting, and Advisory Council support; agencies holding epilepsy data must comply with data requests. The mandate creates administrative and coordination responsibilities for HHS and partner agencies.
• Payers and health systems: Could face changes in recommended care pathways or screening that influence service demand; specific cost impacts are not authorized by the text itself.

Implementation considerations:

• No explicit appropriation language is included, so effective resourcing will depend on existing program funds or future appropriations and administrative prioritization.
• Data sharing requirements improve information availability but may require technical work to standardize and transfer data across agencies.
• The sunset date (December 31, 2035) limits the program’s statutory lifetime and creates a future decision point for Congress on continuation or modification.